Genmab As Stock Short Ratio
| GNMSF Stock | USD 224.00 7.20 3.32% |
Genmab AS fundamentals help investors to digest information that contributes to Genmab AS's financial success or failures. It also enables traders to predict the movement of Genmab Pink Sheet. The fundamental analysis module provides a way to measure Genmab AS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genmab AS pink sheet.
Genmab |
Genmab AS Company Short Ratio Analysis
Genmab AS's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Genmab AS has a Short Ratio of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The short ratio for all United States stocks is 100.0% higher than that of the company.
Genmab Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genmab AS's direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Genmab AS could also be used in its relative valuation, which is a method of valuing Genmab AS by comparing valuation metrics of similar companies.Genmab AS is currently under evaluation in short ratio category among its peers.
Genmab Fundamentals
| Return On Equity | 0.24 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.47 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 26.41 B | |||
| Shares Outstanding | 65.96 M | |||
| Shares Owned By Institutions | 49.90 % | |||
| Price To Earning | 39.08 X | |||
| Price To Book | 7.94 X | |||
| Price To Sales | 2.45 X | |||
| Revenue | 8.48 B | |||
| Gross Profit | 8.48 B | |||
| EBITDA | 4.24 B | |||
| Net Income | 3.01 B | |||
| Cash And Equivalents | 21.61 B | |||
| Cash Per Share | 330.53 X | |||
| Total Debt | 634 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 13.11 X | |||
| Book Value Per Share | 408.67 X | |||
| Cash Flow From Operations | 2.23 B | |||
| Earnings Per Share | 12.00 X | |||
| Price To Earnings To Growth | 1.20 X | |||
| Target Price | 383.57 | |||
| Number Of Employees | 1.56 K | |||
| Beta | 0.67 | |||
| Market Capitalization | 26.78 B | |||
| Total Asset | 24.63 B | |||
| Retained Earnings | (3.96 B) | |||
| Working Capital | 3.72 B | |||
| Current Asset | 4.14 B | |||
| Current Liabilities | 419 M | |||
| Z Score | 25.2 | |||
| Net Asset | 24.63 B |
About Genmab AS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Genmab Pink Sheet
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Genmab Pink Sheet please use our How to Invest in Genmab AS guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.